The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
Open accessAbstract
BACKGROUND: Treatment with rasagiline mesylate, an irreversible monoamine oxidase type B inhibitor, improves symptoms of early Parkinson disease (PD). Preclinical studies suggest that this compound may also modify the progression of PD. OBJECTIVE: To compare the effects of early and later initiation of rasagiline on progression of disability in patients with PD. DESIGN: Double-blind, parallel-group, randomized, delayed-start clinical trial. SETTINGS AND PATIENTS: Four hundred four subjects with early PD, not requiring dopaminergic therapy, enrolled at 32 sites in the United States and Canada. INTERVENTIONS: Subjects were randomized to receive rasagiline, 1 or 2 mg/d, for 1 year or placebo for 6 months followed by rasagiline, 2 mg/d, for 6 months. MAIN OUTCOME MEASURE: Change in total Unified Parkinson's Disease Rating Scale score from baseline to 12 months. RESULTS: Three hundred seventy-one subjects were included in the 1-year efficacy analysis. Subjects treated with rasagiline, 2 mg/d, for 1 year had a 2.29-unit smaller increase in mean adjusted total Unified Parkinson's Disease Rating Scale score compared with subjects treated with placebo for 6 months followed by rasagiline, 2 mg/d, for 6 months (P =.01). The mean adjusted difference between the placebo/rasagiline, 2 mg/d, group and those receiving rasagiline, 1 mg/d, for 1 year was -1.82 unit on the Unified Parkinson's Disease Rating Scale score (P =.05). CONCLUSION: Subjects treated with rasagiline, 2 and 1 mg/d, for 12 months showed less functional decline than subjects whose treatment was delayed for 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Amantadine in the Treatment of Parkinson's Disease
Schwab, R. S. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160070046011 · Cited by 664
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Akao, Y., Maruyama, W., Shimizu, S., Yi, H., Nakagawa, Y., Shamoto‐Nagai, M., Youdim, M. B. H., Tsujimoto, Y., & Naoi, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01047.x · Cited by 166
Neuroprotection by propargylamines in Parkinson's disease
Maruyama, W., Akao, Y., Carrillo, M.-C., Kitani, K., Youdium, M. B. H., & Naoi, M. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00221-0 · Cited by 154
Huang, W., Chen, Y., Shohami, E., & Weinstock, M. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00929-7 · Cited by 141
Youdim, M. B. H., WADIA, A., Tatton, W. G., & Weinstock, M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03656.x · Cited by 140
Akao, Y., Maruyama, W., Yi, H. L., Shamoto‐Nagai, M., Youdim, M. B. H., & Naoi, M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00332-4 · Cited by 131
Effect of lazabemide on the progression of disability in early Parkinson's disease
Kieburtz (1996) · Annals of Neurology · doi:10.1002/ana.410400116 · Cited by 113
Slowing the progression of Alzheimer disease: methodologic issues.
Leber, P. D. (1997) · PubMed · Cited by 104
TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B
Finberg, J. P. M., Tenne, M., & Youdim, M. B. H. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb16772.x · Cited by 103
Abu‐Raya, S., Blaugrund, E., Trembovler, V., Bloch‐Shilderman, E., Shohami, E., & Lazarovici, P. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991101)58:3<456::aid-jnr12>3.0.co;2-s · Cited by 89
Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline
Maruyama, W., Yamamoto, T., Kitani, K., Carrillo, M. C., Youdim, M. B. H., & Naoi, M. (2000) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00144-5 · Cited by 86
Heikkila, R. E., Duvoisin, R. C., Finberg, J. P. M., & Youdim, M. B. H. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90168-2 · Cited by 72
Cited by
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
The therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Metadata
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2004-04-01
- Volume
- 61
- Issue
- 4
- Pages
- 561
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2786305788
- Cited by
- 485
- References
- 18
- FWCI
- 28.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.